Effective January 1, 2025, patients with Aetna® Medicare Advantage or SilverScript® coverage who have metastatic hormone-sensitive prostate cancer (mHSPC) and are new to NUBEQA® are subject to new prior authorization (PA) criteria. Some patients may be required to step through another medication before a PA for NUBEQA is approved.